MCM
DMIIU

Moore Capital Management’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Moore Capital Management’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-750,000
Closed -$7.46M – 874
2025
Q3 		$7.46M Buy
+750,000
New +$7.48M 0.1% 184

Other funds holding DMIIU

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SCM
Steadfast Capital Management New York $3.26B AUM 36.54% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

Moore Capital Management's DMIIU Position: Q4 2025 in Review

Moore Capital Management sold out of Drugs Made In America Acquisition II Corp Unit (DMIIU) in Q4 2025, closing a stake of 750,000 shares — an estimated $7.46M sold.

Moore Capital Management first reported a position in DMIIU in Q3 2025 and held it in 1 quarter. The position peaked at $7.46M in Q3 2025. 30 funds tracked by Wall St. Rank hold DMIIU as of Q4 2025.

  • Moore Capital Management reported no remaining Drugs Made In America Acquisition II Corp Unit position as of Q4 2025 after selling out during the quarter.
  • Moore Capital Management sold 750,000 Drugs Made In America Acquisition II Corp Unit shares in Q4 2025, an estimated $7.46M.
  • Moore Capital Management first reported a position in Drugs Made In America Acquisition II Corp Unit in Q3 2025 and held it in 1 quarter.
  • Moore Capital Management's Drugs Made In America Acquisition II Corp Unit position peaked at $7.46M in Q3 2025.
  • 30 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q4 2025.

Based on Moore Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.